Drug Trial Radar · NCT05618808
A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants
Last checked: Nov 19, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
373
Actual
Start
May 24, 2023
Primary completion
May 27, 2024
Study completion May 27, 2024
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the efficacy of REGN9933 for the prevention of venous thromboembolism (VTE) after unilateral total knee arthroplasty (TKA), compared to enoxaparin The secondary objectives of the study are: * To evaluate the bleeding risk (ie, major and clinically relevant non-major \[CRNM\] bleeding) of REGN9933 after unilateral TKA through time of venography, compared to enoxaparin * To assess overall safety and tolerability of REGN9933 in participants undergoing TKA * To evaluate the efficacy of REGN9933 in prevention of clinically relevant VTE, compared to enoxaparin * To evaluate the efficacy of REGN9933 in prevention of deep venous thrombosis (DVT) detected by venography, compared to enoxaparin * To evaluate the pharmacokinetics (PK) of REGN9933 after single intravenous (IV) administration * To assess pharmacodynamic (PD) effects of REGN9933 on intrinsic and extrinsic coagulation pathways * To assess immunogenicity following a single dose of REGN9933 over time * To compare the efficacy of enoxaparin and apixaban in prevention of VTE after unilateral TKA
Conditions
- Venous Thromboembolism
Interventions
REGN9933Drug
Participants will receive a single dose of REGN9933 by IV infusion
EnoxaparinDrug
Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)
ApixibanDrug
Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) (REGN9933 vs Enoxaparin)Time frame: Through Day 12
Locations
16 sites in 7 countries. Site status is shown where the registry gives one.
Ziekenhuis Oost-Limburg- Campus Sint-Jan
Genk, Limburg, Belgium
MBAL Heart and Brain Hospital
Pleven, Bulgaria
Durham Bone and Joint Specialists
Ajax, Ontario, Canada
Department of Orthopedics, Somogy County Mór Kaposi Teaching Hospital
Kaposvár, Hungary
MAV Korhaz es Rendelointezet Szolnok
Szolnok, Jász-Nagykun-Szolnok, Hungary
Liepaja Regional Hospital
Liepāja, Latvia
Vidzemes Hospital
Riga, Latvia
Riga's 2nd Hospital
Riga, Latvia
Hospital of Traumatology and Orthopaedics
Riga, Latvia
Lietuvos Sveikatos Mokslu Universiteto Kauno Ligoninė
Kaunas, Lithuania
Lietuvos Sveikatos Mokslu Universiteto Ligonine Kauno Klinik
Kaunas, Kaunas County, Lithuania
Klaipeda University Hospital
Klaipėda, Klaipėda County, Lithuania
SP ZOZ Centralny Szpital Kliniczny UM w Lodzi
Lodz, Poland
Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie
Lublin, Poland
Samodzielny Publiczny Zaklad Opieki Zdrowotnej w Radzyniu Podlaskim
Radzyń Podlaski, Poland
Specjalistyczny Szpital im. E. Szczeklika w Tarnowie
Tarnów, Lesser Poland Voivodeship, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.